Glucagon-like peptide-1 agonist
From Wikipedia, the free encyclopedia
There is some concern over the safety profile of these drugs due to proliferative effects in the pancreas 
Licensed GLP-1 agonists:
- exenatide (Byetta/Bydureon), licensed in 2005/2012
- liraglutide (Victoza), licensed 2010
- lixisenatide (Lyxumia), licensed in EU 2013
- albiglutide (Tanzeum), licensed in 2014 by GSK
Under investigation: 
- taspoglutide, phase III halted Sept 2010,
- Baggio et al. (2008). "Glucagon-like Peptide-1 Analogs Other Than Exenatide".
- American Diabetes Association (2011). "Standards of Medical Care in Diabetes--2012". Diabetes Care 35: S11–S63. doi:10.2337/dc12-s011. PMID 22187469.
- "FDA Approves New Treatment for Type 2 Diabetes".
- "Sanofi New Drug Application for Lixisenatide Accepted for Review by FDA".
- "FDA Approves Weekly Injectable Diabetes Drug: Albiglutide".
|This drug article relating to the gastrointestinal system is a stub. You can help Wikipedia by expanding it.|